Your endometrium can be ready again
Ingenes' advanced technique that regenerates endometrial tissue with growth factors and stem cells. A new opportunity for those who have faced implantation failures or an unresponsive endometrium.
Endogen™ is the endometrial regeneration technique developed at Ingenes that uses growth factors and stem cells to improve the quality and receptivity of the endometrium, the tissue where the embryo implants.
A real solution for women with thin or refractory endometrium, Asherman Syndrome, or recurrent implantation failures. Pioneers of the treatment in Latin America, with scientific support published in international journals.
- 0% of patients improve endometrial quality and thickness
- 0% higher pregnancy chances with Endogen™
- 0M stem cells per application in uterine tissue
- 0-3 applications for significant improvement
Small tissue, big decision
The endometrium is the inner layer of the uterus where the embryo implants. Its quality and receptivity determine whether implantation occurs and pregnancy progresses.
-
Endometrial quality
A healthy endometrium needs the right thickness, good vascularization, and proper hormonal response. Without these, the embryo cannot adhere correctly.
-
Uterine receptivity
The uterus has a specific implantation window. If the endometrium is not receptive at that exact moment, even healthy embryos may not implant.
-
Environment for development
Beyond implantation, the endometrium must sustain the embryo in its first weeks. A tissue in good condition reduces the risk of early loss.
A new opportunity when implantation has failed
Endogen™ is designed for women with endometrial diagnoses affecting implantation: Asherman Syndrome, refractory or atrophic endometrium, recurrent implantation failures in IVF cycles, or losses associated with endometrial issues.
The initial diagnosis includes hormonal studies, ultrasounds, and a thorough review of the clinical history. Your Assisted Reproduction specialist confirms whether Endogen™ is the right option for your case.
- Asherman Syndrome (uterine scarring from infections or previous surgeries)
- Refractory or atrophic endometrium that doesn't respond to stimulation
- Implantation failures in previous In Vitro Fertilization cycles
- Recurrent losses associated with low endometrial quality
- Patients with previous uterine surgeries (curettage, myomectomies)
Endogen™ figures at Ingenes
Success rates among the highest worldwide, even above those published in international medical literature.
- Endometrial quality
95% of patients improve
In 95% of cases we manage to improve endometrial quality and thickness thanks to Endogen™, even in patients who did not respond to conventional hormonal treatments.
- Pregnancy probability
68.3% more chances
Endogen™ increases pregnancy probability by 68.3% in patients who faced recurrent implantation failures or low endometrial quality.
- Scientific research
International publications
Results published in Fertility and Sterility (ASRM) and World Journal of Clinical Cases, validating the technique with peer-reviewed evidence.
Your path is unique. So is your plan.
We design a protocol tailored to you after understanding your story and your previous tests. No generic diagnoses or protocols.
Science that regenerates endometrial tissue
Endogen™ combines two regenerative approaches depending on the case: endogenous growth factors (PRP) and stem cells. The specialist determines which fits your diagnosis best.
-
Growth factors (PRP)
We apply platelet-rich plasma obtained from the patient herself, loaded with proteins that stimulate the development of new healthy cells and improve endometrial vascularization. 2-3 applications are usually enough for significant improvement.
-
Mesenchymal stem cells
For more complex cases such as severe Asherman Syndrome or refractory endometrium, we apply 10 million stem cells in the uterine tissue. They regenerate damaged tissue and restore endometrial receptivity.
-
Personalized follow-up
The specialist monitors tissue development after each application, adjusting the treatment based on endometrial response to maximize results.
Pioneers in endometrial regeneration in Latin America
At Ingenes we have published Endogen™ results in collaboration with Cinvestav-IPN in international peer-reviewed scientific journals, including studies on mesenchymal stem cells and platelet-rich plasma in patients with refractory endometrium and Asherman Syndrome.
Recently, the first babies conceived at Ingenes with allogeneic stem cells were born, marking a new milestone in advanced endometrial regeneration.
- Publications in Fertility and Sterility (ASRM Congress)
- Studies in World Journal of Clinical Cases on endometrial receptivity
- Collaboration with Cinvestav-IPN in stem cell research
- First babies at Ingenes born with allogeneic stem cells
Frequently asked questions
How does endometrial regeneration work?
Endogen™ uses growth factors from the patient's own plasma (PRP) or mesenchymal stem cells to regenerate endometrial tissue. The treatment stimulates the development of new healthy cells and improves vascularization, optimizing uterine receptivity so the embryo can implant.
When is Endogen™ indicated?
It is indicated for women with Asherman Syndrome, refractory or atrophic endometrium, recurrent implantation failures in In Vitro Fertilization cycles, and losses associated with endometrial issues. The initial diagnosis confirms this with ultrasounds and hormonal studies.
How many applications are needed?
With growth factors (PRP) usually 2-3 applications for significant improvement. With stem cells, the amount depends on the diagnosis. In all cases, the specialist monitors tissue development and adjusts the treatment based on the response.
What are the success rates?
In 95% of patients Endogen™ improves endometrial quality and thickness, and increases pregnancy probability by 68.3%. Our rates are among the highest internationally, above those reported in medical literature.
What scientific support does Endogen™ have?
Endogen™ has publications in indexed scientific journals such as Fertility and Sterility (American Society for Reproductive Medicine) and World Journal of Clinical Cases. The studies were developed in collaboration with Cinvestav-IPN and validate both the use of PRP and mesenchymal stem cells.
Does your endometrium need a new opportunity?
Book your first consultation to evaluate whether Endogen™ is the best option for your case. We walk with you with science and experience from day one.
Contact us